Chemical and functional analysis of generic hydroxyurea formulations

Area of Science:

• Pharmacology
• Hematology
• Pediatrics

Background:

• Sickle cell anemia (SCA) is a debilitating genetic blood disorder disproportionately affecting children.
• Hydroxyurea is a known effective treatment for SCA, offering potential as an inexpensive option for resource-limited settings.
• Concerns regarding the quality and consistency of generic hydroxyurea formulations from various international manufacturers necessitate rigorous evaluation.

Purpose of the Study:

• To assess the quality and consistency of generic hydroxyurea capsules from different international pharmaceutical sources.
• To determine if product variability among vendors impacts the efficacy of hydroxyurea for treating pediatric sickle cell anemia.

Main Methods:

• Quantitative chemical assays were employed to analyze hydroxyurea capsule composition.
• Functional assays were conducted to evaluate the therapeutic potential of the analyzed samples.
• Eight different pharmaceutical sources of hydroxyurea capsules were included in the study.

Main Results:

• All analyzed hydroxyurea samples consistently met expected results within a 20% margin.
• No significant variations in quality or efficacy were detected among the different international vendors.
• The study confirmed the reliability of generic hydroxyurea formulations.

Conclusions:

• Generic hydroxyurea formulations demonstrate consistent quality and therapeutic potential, making them a viable and inexpensive treatment for pediatric sickle cell anemia globally.
• The findings alleviate concerns about product variability, supporting the widespread use of generic hydroxyurea in managing SCA, particularly in resource-limited regions.
• Hydroxyurea remains a potent and accessible therapeutic option for children with SCA worldwide.